Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.46 | — | — | — | — | — | — | — | — | — | — | 0.02 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 300.07 | — | — | 169.38 | 106.21 | — | 545.24 | — | 339.73 | 67.42 | 131.61 | 460.92 | 802.96 |
| — | — | — | — | -68.7% | — | +314.3% | — | -57.7% | -52.3% | -91.5% | -96.1% | -78.6% | |
| P/B Ratio | 0.72 | — | 2.78 | 0.86 | 0.73 | 2.21 | 2.27 | 3.42 | 1.19 | 0.76 | 0.70 | 1.06 | 1.80 |
| — | — | +22.2% | -74.8% | -39.0% | +191.7% | +223.4% | +221.8% | -34.0% | -96.1% | -95.7% | -96.0% | -94.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | 100.0% | -563.1% | — | -722.4% | — | -70.7% | 100.0% | 100.0% | -902.3% | -981.7% |
| — | — | — | — | -696.5% | — | -822.4% | — | +92.8% | 0.0% | 0.0% | -1002.3% | -1425.3% | |
| Operating Margin | -51616.9% | — | — | -38337.0% | -17410.8% | — | -32945.9% | — | -26686.3% | -9152.6% | -16392.0% | -38238.2% | -44876.8% |
| — | — | — | — | +34.8% | — | -101.0% | — | +40.5% | -2243.2% | -23.5% | -6.1% | -256.9% | |
| Net Margin | -49254.3% | — | — | -30140.5% | -16566.4% | — | -31993.3% | — | -24357.9% | -8734.8% | -15725.3% | -35364.8% | -43687.2% |
| — | — | — | — | +32.0% | — | -103.5% | — | +44.2% | -2016.2% | -13.7% | +11.0% | -242.8% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -115.4% | -437.2% | -59.0% | -32.9% | -27.3% | -29.6% | -33.7% | -28.8% | -19.6% | -22.1% | -19.3% | -19.3% | -22.3% |
| — | -1379.3% | -74.8% | -14.3% | -39.4% | -34.0% | -74.9% | -49.2% | +12.1% | -64.8% | +42.0% | +8.0% | +11.2% | |
| ROA | -75.5% | -66.1% | -30.2% | -19.6% | -17.6% | -20.9% | -24.5% | -20.3% | -13.7% | -15.9% | -14.2% | -13.2% | -14.7% |
| — | -216.4% | -23.3% | +3.3% | -28.1% | -31.2% | -72.4% | -53.7% | +6.6% | -79.4% | +40.7% | +21.3% | +29.0% | |
| ROIC | -114.1% | — | -92.5% | -101.1% | -38.7% | -29.4% | -30.4% | -21.3% | -14.6% | -18.0% | -15.9% | -16.1% | -17.3% |
| — | — | -203.8% | -374.3% | -166.3% | -63.4% | -91.5% | -32.7% | +15.9% | -90.1% | +37.0% | -3.2% | +14.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 79.7% YoY to 0.79x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | — | 0.37 | 0.22 | 0.17 | 0.17 | 0.13 | 0.14 | 0.26 | 0.22 | 0.18 | 0.16 | 0.14 |
| — | — | +178.4% | +54.7% | -32.7% | -21.5% | -26.1% | -9.1% | +78.5% | +77.4% | +62.3% | +65.1% | +74.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.77 | 0.79 | 1.66 | 2.63 | 2.77 | 3.88 | 4.45 | 4.77 | 3.60 | 4.00 | 3.91 | 4.24 | 3.25 |
| — | -79.7% | -62.7% | -44.9% | -23.0% | -2.8% | +13.8% | +12.5% | +10.5% | +8.4% | +23.3% | -37.0% | -52.3% | |
| Quick Ratio | 2.77 | 0.79 | 1.66 | 2.63 | 2.77 | 3.88 | 4.45 | 4.77 | 3.60 | 4.00 | 3.91 | 4.24 | 3.25 |
| — | -79.7% | -62.7% | -44.9% | -23.0% | -2.8% | +13.8% | +12.5% | +10.5% | +8.4% | +23.3% | -37.0% | -52.3% | |
| Interest Coverage | -632.05 | — | — | — | — | — | — | -177.05 | -97.03 | -113.41 | -118.16 | -140.20 | -178.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonInovio Pharmaceuticals, Inc.'s current P/E is -0.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Inovio Pharmaceuticals, Inc.'s current operating margin is -51616.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Inovio Pharmaceuticals, Inc.'s business trajectory between earnings reports.